- Médunik Canada became the exclusive Canadian distributor of Increlex (mecasermin) through a partnership with ESTEVE, ensuring continued access for patients.
- Increlex is indicated for children and adolescents (2–18 years) with severe primary IGF-1 deficiency (SPIGFD), a rare disorder causing impaired growth.
- Médunik will continue the existing patient support program, helping ensure uninterrupted treatment and support for patients and caregivers.
- The partnership reinforces both companies’ commitment to improving care and access for Canadians living with rare endocrine diseases.
Takeaways
Médunik Canada’s exclusive distribution of Increlex (mecasermin) with ESTEVE ensures that children and adolescents with severe primary IGF‑1 deficiency in Canada can continue to access this rare disease therapy.
Médunik will maintain the existing patient support program to support uninterrupted treatment and caregiver assistance, while the partnership strengthens access to a specialized endocrine product for a small, high‑need population in the rare disease space.
Source: PRnewswire
